Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Income Taxes

Microsoft Excel

Income Tax Expense (Benefit)

Gilead Sciences Inc., income tax expense (benefit), continuing operations

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Federal 1,781 2,539 1,776 1,450 1,646
State 80 32 228 198 135
Foreign 381 232 185 155 124
Current 2,242 2,803 2,189 1,803 1,905
Federal (1,126) (1,502) (250) (164) (843)
State 170 (154) 185 (97) (42)
Foreign (39) 101 (47) 38 (1,224)
Deferred (995) (1,555) (112) (223) (2,109)
Income tax expense (benefit) 1,247 1,248 2,077 1,580 (204)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Current Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations. Gilead Sciences Inc. current increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Deferred Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. Gilead Sciences Inc. deferred decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Income tax expense (benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Gilead Sciences Inc. income tax expense (benefit) decreased from 2021 to 2022 and from 2022 to 2023.

Effective Income Tax Rate (EITR)

Gilead Sciences Inc., effective income tax rate (EITR) reconciliation

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Federal statutory tax rate 21.00% 21.00% 21.00% 21.00% 21.00%
State taxes, net of federal benefit 2.30% -2.00% 2.50% 4.20% 0.40%
Foreign earnings at different rates -0.20% -0.60% -0.30% -10.00% 2.50%
Research and other credits -4.30% -2.70% -1.60% -6.90% -1.90%
US tax on foreign earnings 1.00% 2.70% 1.10% 7.20% 4.30%
Foreign-derived intangible income deduction -2.10% -3.80% -1.60% -8.00% -3.20%
Tax examinations -4.70% -0.20% -0.70% -10.20% -2.40%
Acquired IPR&D & related charges 1.30% 1.40% 0.00% 56.20% 0.00%
Changes in valuation allowance 0.90% 1.20% 1.50% 6.70% 0.00%
Non-taxable unrealized (gain) loss on investment 0.20% 0.70% 1.80% 23.00% -5.00%
Other 2.80% 3.80% 1.40% 11.50% -19.70%
Effective tax rate 18.20% 21.50% 25.10% 94.70% -4.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Effective tax rate Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Gilead Sciences Inc. effective tax rate decreased from 2021 to 2022 and from 2022 to 2023.

Components of Deferred Tax Assets and Liabilities

Gilead Sciences Inc., components of deferred tax assets and liabilities

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net operating loss carryforwards 417 430 413 587 184
Stock-based compensation 94 95 117 113 113
Reserves and accruals not currently deductible 644 645 700 444 423
Excess of tax basis over book basis of intangible assets 1,041 1,067 1,157 1,177 1,232
Upfront and milestone payments 1,271 1,298 1,310 1,144 988
Research and other credit carryforwards 283 233 249 219 247
Equity investments 221 196 117 116
Liability related to future royalties 296 278 274 247
Capitalized R&D expenditures 1,623 784
Other, net 320 263 292 311 168
Deferred tax assets before valuation allowance 6,210 5,289 4,629 4,358 3,355
Valuation allowance (663) (599) (520) (398) (217)
Deferred tax assets 5,547 4,690 4,109 3,960 3,138
Property, plant and equipment (274) (234) (227) (202) (88)
Excess of book basis over tax basis of intangible assets (5,481) (5,728) (6,719) (6,168) (1,401)
Other (184) (160) (180) (202) (93)
Deferred tax liabilities (5,939) (6,122) (7,126) (6,572) (1,582)
Net deferred tax assets (liabilities) (392) (1,432) (3,017) (2,612) 1,556

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Deferred tax assets before valuation allowance Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Gilead Sciences Inc. deferred tax assets before valuation allowance increased from 2021 to 2022 and from 2022 to 2023.
Deferred tax assets Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Gilead Sciences Inc. deferred tax assets increased from 2021 to 2022 and from 2022 to 2023.
Net deferred tax assets (liabilities) Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. Gilead Sciences Inc. net deferred tax assets (liabilities) increased from 2021 to 2022 and from 2022 to 2023.

Deferred Tax Assets and Liabilities, Classification

Gilead Sciences Inc., deferred tax assets and liabilities, classification

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Deferred tax asset 1,196 1,241 1,339 1,302 1,556
Deferred tax liability 1,588 2,673 4,356 3,914

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Deferred tax asset Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent. Gilead Sciences Inc. deferred tax asset decreased from 2021 to 2022 and from 2022 to 2023.
Deferred tax liability Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent. Gilead Sciences Inc. deferred tax liability decreased from 2021 to 2022 and from 2022 to 2023.

Adjustments to Financial Statements: Removal of Deferred Taxes

Gilead Sciences Inc., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Adjustment to Total Assets
Total assets (as reported) 62,125 63,171 67,952 68,407 61,627
Less: Noncurrent deferred tax assets, net 1,196 1,241 1,339 1,302 1,556
Total assets (adjusted) 60,929 61,930 66,613 67,105 60,071
Adjustment to Total Liabilities
Total liabilities (as reported) 39,376 41,962 46,888 50,186 38,977
Less: Noncurrent deferred tax liabilities, net 1,588 2,673 4,356 3,914
Total liabilities (adjusted) 37,788 39,289 42,532 46,272 38,977
Adjustment to Total Gilead Stockholders’ Equity
Total Gilead stockholders’ equity (as reported) 22,833 21,240 21,069 18,202 22,525
Less: Net deferred tax assets (liabilities) (392) (1,432) (3,017) (2,612) 1,556
Total Gilead stockholders’ equity (adjusted) 23,225 22,672 24,086 20,814 20,969
Adjustment to Net Income Attributable To Gilead
Net income attributable to Gilead (as reported) 5,665 4,592 6,225 123 5,386
Add: Deferred income tax expense (benefit) (995) (1,555) (112) (223) (2,109)
Net income attributable to Gilead (adjusted) 4,670 3,037 6,113 (100) 3,277

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


Gilead Sciences Inc., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)

Gilead Sciences Inc., adjusted financial ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net Profit Margin
Reported net profit margin 21.03% 17.02% 23.05% 0.51% 24.35%
Adjusted net profit margin 17.34% 11.26% 22.63% -0.41% 14.82%
Total Asset Turnover
Reported total asset turnover 0.43 0.43 0.40 0.36 0.36
Adjusted total asset turnover 0.44 0.44 0.41 0.36 0.37
Financial Leverage
Reported financial leverage 2.72 2.97 3.23 3.76 2.74
Adjusted financial leverage 2.62 2.73 2.77 3.22 2.86
Return on Equity (ROE)
Reported ROE 24.81% 21.62% 29.55% 0.68% 23.91%
Adjusted ROE 20.11% 13.40% 25.38% -0.48% 15.63%
Return on Assets (ROA)
Reported ROA 9.12% 7.27% 9.16% 0.18% 8.74%
Adjusted ROA 7.66% 4.90% 9.18% -0.15% 5.46%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Financial ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by total revenue. Gilead Sciences Inc. adjusted net profit margin ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Gilead Sciences Inc. adjusted total asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023.
Adjusted financial leverage A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity.
Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.
Gilead Sciences Inc. adjusted financial leverage ratio decreased from 2021 to 2022 and from 2022 to 2023.
Adjusted ROE A profitability ratio calculated as adjusted net income divided by adjusted shareholders’ equity. Gilead Sciences Inc. adjusted ROE deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.
Adjusted ROA A profitability ratio calculated as adjusted net income divided by adjusted total assets. Gilead Sciences Inc. adjusted ROA deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.

Gilead Sciences Inc., Financial Ratios: Reported vs. Adjusted


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead 5,665 4,592 6,225 123 5,386
Product sales 26,934 26,982 27,008 24,355 22,119
Profitability Ratio
Net profit margin1 21.03% 17.02% 23.05% 0.51% 24.35%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead 4,670 3,037 6,113 (100) 3,277
Product sales 26,934 26,982 27,008 24,355 22,119
Profitability Ratio
Adjusted net profit margin2 17.34% 11.26% 22.63% -0.41% 14.82%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 Net profit margin = 100 × Net income attributable to Gilead ÷ Product sales
= 100 × 5,665 ÷ 26,934 = 21.03%

2 Adjusted net profit margin = 100 × Adjusted net income attributable to Gilead ÷ Product sales
= 100 × 4,670 ÷ 26,934 = 17.34%

Profitability ratio Description The company
Adjusted net profit margin An indicator of profitability, calculated as adjusted net income divided by total revenue. Gilead Sciences Inc. adjusted net profit margin ratio deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.

Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Product sales 26,934 26,982 27,008 24,355 22,119
Total assets 62,125 63,171 67,952 68,407 61,627
Activity Ratio
Total asset turnover1 0.43 0.43 0.40 0.36 0.36
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Product sales 26,934 26,982 27,008 24,355 22,119
Adjusted total assets 60,929 61,930 66,613 67,105 60,071
Activity Ratio
Adjusted total asset turnover2 0.44 0.44 0.41 0.36 0.37

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 Total asset turnover = Product sales ÷ Total assets
= 26,934 ÷ 62,125 = 0.43

2 Adjusted total asset turnover = Product sales ÷ Adjusted total assets
= 26,934 ÷ 60,929 = 0.44

Activity ratio Description The company
Adjusted total asset turnover An activity ratio calculated as total revenue divided by adjusted total assets. Gilead Sciences Inc. adjusted total asset turnover ratio improved from 2021 to 2022 and from 2022 to 2023.

Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Total assets 62,125 63,171 67,952 68,407 61,627
Total Gilead stockholders’ equity 22,833 21,240 21,069 18,202 22,525
Solvency Ratio
Financial leverage1 2.72 2.97 3.23 3.76 2.74
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted total assets 60,929 61,930 66,613 67,105 60,071
Adjusted total Gilead stockholders’ equity 23,225 22,672 24,086 20,814 20,969
Solvency Ratio
Adjusted financial leverage2 2.62 2.73 2.77 3.22 2.86

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 Financial leverage = Total assets ÷ Total Gilead stockholders’ equity
= 62,125 ÷ 22,833 = 2.72

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Gilead stockholders’ equity
= 60,929 ÷ 23,225 = 2.62

Solvency ratio Description The company
Adjusted financial leverage A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity.
Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.
Gilead Sciences Inc. adjusted financial leverage ratio decreased from 2021 to 2022 and from 2022 to 2023.

Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead 5,665 4,592 6,225 123 5,386
Total Gilead stockholders’ equity 22,833 21,240 21,069 18,202 22,525
Profitability Ratio
ROE1 24.81% 21.62% 29.55% 0.68% 23.91%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead 4,670 3,037 6,113 (100) 3,277
Adjusted total Gilead stockholders’ equity 23,225 22,672 24,086 20,814 20,969
Profitability Ratio
Adjusted ROE2 20.11% 13.40% 25.38% -0.48% 15.63%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 ROE = 100 × Net income attributable to Gilead ÷ Total Gilead stockholders’ equity
= 100 × 5,665 ÷ 22,833 = 24.81%

2 Adjusted ROE = 100 × Adjusted net income attributable to Gilead ÷ Adjusted total Gilead stockholders’ equity
= 100 × 4,670 ÷ 23,225 = 20.11%

Profitability ratio Description The company
Adjusted ROE A profitability ratio calculated as adjusted net income divided by adjusted shareholders’ equity. Gilead Sciences Inc. adjusted ROE deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.

Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead 5,665 4,592 6,225 123 5,386
Total assets 62,125 63,171 67,952 68,407 61,627
Profitability Ratio
ROA1 9.12% 7.27% 9.16% 0.18% 8.74%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead 4,670 3,037 6,113 (100) 3,277
Adjusted total assets 60,929 61,930 66,613 67,105 60,071
Profitability Ratio
Adjusted ROA2 7.66% 4.90% 9.18% -0.15% 5.46%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 ROA = 100 × Net income attributable to Gilead ÷ Total assets
= 100 × 5,665 ÷ 62,125 = 9.12%

2 Adjusted ROA = 100 × Adjusted net income attributable to Gilead ÷ Adjusted total assets
= 100 × 4,670 ÷ 60,929 = 7.66%

Profitability ratio Description The company
Adjusted ROA A profitability ratio calculated as adjusted net income divided by adjusted total assets. Gilead Sciences Inc. adjusted ROA deteriorated from 2021 to 2022 but then improved from 2022 to 2023 not reaching 2021 level.